Guys its not about spiting a junior biotech
Its about scale - IMU isnt even a flea on Novartis' elephant, its a pimple on the flea.
I often am amused by biotech shareholders looking at their companies with delusions of grandeur
The tech is miles away from market, big pharma needs to hit quarterlies, its unlikely the CEO of Novartis even has heard of IMU. Its a common defensive play and one that I would take anytime.
Why do I still hold and suggest buying? There is still hope while the company is breathing. I do think they needed to commercialise it themselves, they dont have the skill set though
takeover?, page-13
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |